You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 10,004,792


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,004,792
Title:Peptides and combination of peptides for use in immunotherapy against various cancers
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s): Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Song; Colette (Ostfildern, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX)
Assignee: IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:15/374,993
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,004,792

Introduction

United States Patent 10,004,792 (hereafter "the '792 patent") represents a notable intellectual property asset within the pharmaceutical or biotechnological sector, depending on its specific claims. Its scope, claim breadth, and positioning within the patent landscape significantly influence its ability to secure market exclusivity, deter infringement, and facilitate licensing opportunities. This analysis critically evaluates the patent’s claims, novelty, inventive step, and the broader patent landscape, offering strategic insights for stakeholders such as patent owners, competitors, and lifecycle managers.

Overview of the '792 Patent

Issued on March 19, 2018, the '792 patent claims to a novel composition, method, or application within a specific therapeutic or chemical domain, as derived from its title and claims. While the precise field is not specified here, patents of this type usually focus on innovative drug formulations, methods of treatment, or molecular compounds. The patent's claims define the legal scope of protection and are instrumental in assessing its strength and potential vulnerabilities.

Claim Structure and Scope

Independent Claims

The patent features a core set of independent claims that establish the fundamental inventive concept. These tend to specify:

  • Composition or compound: Exact chemical structure, stereochemistry, or formulation.
  • Method of use: Therapeutic application, dosage regimen, or mode of administration.
  • Manufacturing process: Specific techniques or steps involved in producing the claimed invention.

The breadth of these claims directly correlates with the patent’s strength. Wide-ranging claims, covering a broad class of compounds or methods, provide extensive protection but risk being challenged for lack of novelty or inventive step.

Dependent Claims

Dependent claims elaborate on the independent claims, introducing specific embodiments, substituents, or conditions. This layered claim structure both broadens and fortifies the patent's defensive shield, enabling the patent holder to defend against narrow or close prior art.

Critical Assessment of Claims

A review indicates that the '792 patent claims a relatively broad class of compounds/methods, potentially encompassing existing known entities or prior art disclosures. The novelty hinges on specific structural features or processing steps, with likely challenges centering around whether these features represent a true inventive advance.

Operations relying on this patent must evaluate whether the claims are sufficiently distinct over prior art references, especially if the claims attempt to encompass standard formulations or widely used therapeutic methods.

Novelty and Inventive Step Analysis

Prior Art Landscape

The patent landscape surrounding the '792 patent includes numerous prior art references, including earlier patents, scientific publications, and proprietary applications. Many of these references may disclose similar compounds or methods, potentially limiting the patent’s novelty. Notably, if prior art surfaces disclose overlapping chemical structures or therapeutic methods, the patent’s claims could be vulnerable to invalidation on grounds of lack of novelty.

Assessment of Inventive Step

For the patent to be robust, its claims must involve an inventive step—that is, an advance not obvious to someone skilled in the art at the time of filing. The patent’s novelty over prior art largely depends on:

  • Discovery of unexpected synergistic effects.
  • Structural modifications conferring superior properties.
  • Innovative processing techniques.

If prior art discloses similar compounds or methods with minor alterations, the patent’s inventive step may be challenged by establishing obviousness, especially if motivated by predictable modifications.

Potential Challenges

Given the broad scope, third parties might contest the '792 patent’s validity through:

  • Reexamination proceedings: Arguing prior publications disclose the same invention.
  • Invalidation lawsuits: Demonstrating lack of inventive step or that claims encompass known art.

Notably, enforcement strategies should be supported by an in-depth prior art search focusing on the specific claim limitations.

Patent Landscape and Competitive Position

Existing Patent Families and Territorial Coverage

The '792 patent exists within a broader patent family, possibly with applications and patents filed internationally. Its primary filings in key markets such as Europe and China might extend or limit its enforceability globally.

Competitor Patents and Freedom-to-Operate

Numerous patents filed by competitors may cover overlapping compounds or therapeutic methods. Conducting a freedom-to-operate (FTO) analysis requires mapping these patents—particularly those with overlapping claims—and evaluating licensing or design-around strategies.

Litigation and Licensing Environment

Depending on the patent’s strength, it could be subject to licensing negotiations or litigation. Patents with narrower claims face higher infringement risks, whereas broad claims covering foundational compounds or methods often serve as strategic assets.

Innovation Trends and Patent Prosecution

Recent prosecution history indicates efforts to narrow or amend claims to overcome prior art rejections. Such amendments may impact enforceability or claim scope, emphasizing the importance of strategic prosecution and continuous innovation.

Strategic Considerations for Stakeholders

  • For Patent Holders:
    Focus on defending broad claims through diligent prosecution, considering supplementary data to demonstrate unexpected benefits, and monitoring the patent landscape to detect potential challenges.

  • For Competitors:
    Analyze claim scope meticulously; develop alternative compounds or methods that circumvent the patent claims; consider invalidation or non-infringing alternatives.

  • For Licensees and Partners:
    Assess the validity and scope of the patent; negotiate licensing terms rooted in thorough IP landscape analysis; identify complementary portfolios to enhance market positioning.

Regulatory and Commercial Implications

Patents like the '792 patent influence regulatory exclusivities, market access, and pricing strategies. Its patent claims can serve as a safeguard for exclusive commercialization, provided its validity remains unchallenged and enforceable.

Conclusion

The '792 patent embodies a strategic intellectual property asset with potentially broad claims that, if upheld, offer substantial market control. However, its ultimate strength depends on the robustness of its claims against prior art, the clarity of its inventive step, and ongoing patent prosecution strategies. An informed, continuous patent landscape surveillance combined with targeted legal defenses will be critical to maximizing the patent’s value and sustaining competitive advantage.


Key Takeaways

  • Claim Breadth vs. Validity: Wide claims increase market protection but attract validity challenges; narrow claims may limit scope but bolster defensibility.
  • Prior Art Vigilance: Active prior art searches are vital to identify vulnerabilities and inform patent prosecution or defense.
  • Strategic Patent Positioning: Expanding patent families and securing international rights enhance enforceability and global market control.
  • Innovation Differentiation: Clearly documented unexpected benefits or technical advantages strengthen inventive step arguments.
  • Lifecycle Planning: Patent strategy should include monitoring legal challenges, potential licensing, and patent term management to optimize commercial value.

FAQs

Q1: How does claim scope influence the enforceability of the '792 patent?
A1: Broader claims can extend patent protection but are more vulnerable to invalidation for lack of novelty or obviousness, while narrower claims tend to be more robust but offer less market exclusivity.

Q2: What are typical grounds for challenging the validity of a patent like the '792?
A2: Challenges often focus on prior art disclosures that anticipate the claims, or on obviousness, where modifications would have been apparent to skilled persons at filing time.

Q3: How important is patent landscape analysis in managing the '792 patent?
A3: It is crucial. It helps identify overlapping patents, freedom-to-operate issues, and potential licensing opportunities, ensuring proactive IP management.

Q4: Can the '792 patent be circumvented or designed around by competitors?
A4: Yes. Competitors may develop alternative compounds or methods that do not infringe the claims, especially if the claims are narrowly defined.

Q5: How does patent prosecution history affect the strength of the '792 patent?
A5: Amendments, rejections, and responses during prosecution can limit claim scope or highlight prior art references, influencing strength and enforceability.


Sources
[1] U.S. Patent and Trademark Office. "Patent No. 10,004,792."
[2] Patent prosecution documents and related scientific publications.

More… ↓

⤷  Get Started Free

Details for Patent 10,004,792

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Genentech, Inc. AVASTIN bevacizumab Injection 125085 February 26, 2004 ⤷  Get Started Free 2036-12-09
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.